Nan Fung Group Holdings Ltd

Q1 2024 13F Combination Report, Stock Holdings

Signature - Title
Tang Chun Wai Nelson - Director
Location
Kai Tak, Hong Kong
Holdings as of
31 Mar 2024
Value $
$107,923,568
Num holdings
45
Filing time
14 May 2024, 16:12:55 UTC
Form type
13F-HR
Description
A portion of the US holdings for this investor are reported in this report and a portion are reported by other reporting manager(s). Top holdings included ILMN, HRMY, ALPN, OCS, and LAB.
Previous filing
Q4 2023 - 13 Feb 2024
Next filing
Q2 2024 - 13 Aug 2024
SEC
View on sec.gov
Sym Weight Trade Impact Company Class Share Change Activity Value Change $ Value $ * Price $ Shares Principal
Filing 2024 Q1 compared to 2023 Q4 by default. Changes are calculated vs the previous SEC filing.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.

Person Signing this Report on Behalf of Reporting Manager:

Name Title City, State Date
Tang Chun Wai Nelson Director Kai Tak, Hong Kong 14 May 2024

List of Other Managers Reporting for Nan Fung Group Holdings Ltd:

Name Holdings Value Location File Number
Pivotal bioVenture Partners Fund I U.G.P. Ltd San Francisco, CA 028-20631
Pivotal bioVenture Partners Investment Advisor LLC $258,658,319 San Francisco, CA 028-20630

Other Included Managers (2):

Num Name Location File Number
1 Pivotal bioVenture Partners Investment Advisor LLC San Francisco, CA 028-20630
2 Pivotal bioVenture Partners Fund I U.G.P. Ltd San Francisco, CA 028-20631